Perspectives on Expanding the Evidence Base to Inform Vaccine Introduction: Program Costing and Cost-Effectiveness Analyses
The Pan American Health Organization (PAHO) released a supplement to the scientific journal, Vaccine, which includes research that demonstrates the cost-effectiveness and public health impact of rotavirus vaccines through the ProVac initiative. The ProVac Initiative provides technical support to decision makers and strengthens national capacity to make evidence-based decisions in the context of new vaccine introduction. Sabin's own Executive Vice President, Dr. Jon Andrus, was a major contributor to the publication.
As a member of the ProVac IWG, the Sabin Vaccine Institute has contributed to several country-level cost-effectiveness analyses (CEA) on vaccines such as rotavirus. Sabin is also developing and piloting a strategy to effectively communicate to stakeholders a guide that countries can rely on to provide informed, evidence-based decision making related to vaccine introduction.
The program "includes results from a series of studies that utilized the ProVac method and tools and projected that national rotavirus vaccination programs will be highly cost-effective and substantially reduce child illness and deaths due to rotavirus diarrhea."